Form 4 for FBIO Fortress Biotech, Inc.
Accepted 2023-01-04 00:00:00 ET · period of report 2023-01-01 · accession 0001104659-23-001103 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-01-04 | 2022-06-01+ | FBIO | ROSENWALD LINDSAY A MD | Pres, CEO, COB, Dir, 10% | A - Grant | $0.0025 | +1.22M | 11.73M | +12% | +$3,113 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | COMMON STOCK, PAR VALUE $0.001 | 2023-01-01 | A | A | 1,219,294 | $0.00 | 12,953,882 | D | — | — | (F2) The Reporting Person was granted 1,219,294 restricted shares pursuant to the Issuer's Long-Term Incentive Plan on January 1, 2023. |
| 2 | Common | COMMON STOCK, PAR VALUE $0.001 | 2022-06-01 | A | A | 4,264 | $0.73 | 11,734,588 | D | — | — | (F1) These shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |